Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study
Paul G. Richardson, Simon J. Harrison, Sara Bringhen, Fredrik Schjesvold, Kwee Yong, Frank Campana, Solenn Le-Guennec, Sandrine Macé, Meletios Α. Dimopoulos
Abstract
In the Phase III ICARIA-MM study (NCT02990338), the addition of the anti-CD38 monoclonal antibody isatuximab to pomalidomide and dexamethasone led to increased progression-free survival and improved response rates in patients with relapsed/refractory multiple myeloma. There is an unmet treatment need, particularly among patients with poor prognoses, including those with high-risk cytogenetics, those who have renal impairment, those who are elderly and those who are refractory to prior lines of treatment. In this review, the subgroup analyses from the ICARIA-MM study, representing subpopulations with poor prognostic factors, are discussed. Overall, the addition of isatuximab to pomalidomide and dexamethasone improved progression-free survival and disease response rates across different subgroups, regardless of prognostic factor.